Cerebrospinal fluid markers of idiopathic intracranial hypertension: Is the renin-angiotensinogen system involved?

Cephalalgia

Volumn 31, Issue 1, 2011, Pages 116-121

  Brettschneider, Johannes ^a   Hartmann, Nele ^a   Lehmensiek, Vera ^a   Mogel, Helga ^a   Ludolph, Albert C ^a   Tumani, Hayrettin ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

2 D DIGE; angiotensinogen; cerebrospinal fluid; Idiopathic intracranial hypertension; proteome analysis

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA2 GLYCOPROTEIN; ANGIOTENSINOGEN; BIOLOGICAL MARKER; HAPTOGLOBIN; HEMOPEXIN; IMMUNOGLOBULIN HEAVY CONSTANT ALPHA 1 PROTEIN; PREALBUMIN; PROTEIN; SEROTRANSFERRIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; ZINC ALPHA2 GLYCOPROTEIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC INTRACRANIAL HYPERTENSION; INTRACRANIAL HYPERTENSION; MALE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TWO DIMENSIONAL FLUORESCENCE DIFFERENTIAL GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ADOLESCENT; ADULT; ANGIOTENSINOGEN; BIOLOGICAL MARKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOTUMOR CEREBRI; RENIN-ANGIOTENSIN SYSTEM; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UP-REGULATION; YOUNG ADULT;

EID: 79751503384     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410375726     Document Type: Article

References (40)

1. Skau M., Brennum J., Gjerris F. and Jensen R. What is new about idiopathic intracranial hypertension? An updated review of mechanism and treatment. Cephalalgia 2006 ; 26: 384-399.
2. Sinclair AJ, Ball AK, Burdon MA, et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol 2008 ; 201/202: 212-220.
3. Durcan FJ, Corbett JJ and Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol 1988 ; 45: 875-867.
4. Ireland B., Corbett JJ and Wallace RB The search for causes of idiopathic intracranial hypertension. A preliminary case-control study. Arch Neurol 1990 ; 47: 315-320. (Pubitemid 20098697)
5. Jacobson DM, Berg R., Wall M., Digre KB, Corbett JJ and Ellefson RD Serum vitamin A concentration is elevated in idiopathic intracranial hypertension. Neurology 1999 ; 53: 1114-1118. (Pubitemid 29442133)
6. Reid AC and Thomson JA Absence of significant endocrine deficiencies in benign intracranial hypertension. J Neurol Neurosurg Psychiatry 1981 ; 44: 731-734. (Pubitemid 11028123)
7. Selhorst JB, Kulkantrakorn K., Corbett JJ, Leira EC and Chung SM Retinol-binding protein in idiopathic intracranial hypertension (IIH). J Neuroophthalmol 2000 ; 20: 250-252.
8. Peng JH, Kung FT, Peng W. and Parker Jr JC Increased ALZ-50 immunoreactivity in CSF of pseudotumor cerebri patients. Ann Clin Lab Sci 2006 ; 36: 151-156.
9. Soelberg Sorensen P., Gjerris F. and Svenstrup B. Endocrine studies in patients with pseudotumor cerebri: estrogen levels in blood and cerebrospinal fluid. Arch Neurol 1986 ; 43: 902-906. (Pubitemid 16047023)
10. Ball AK, Sinclair AJ, Curnow SJ, et al. Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance? Clin Endocrinol (Oxf) 2009 ; 70: 863-869.
11. Dhungana S., Sharrack B. and Woodroofe N. Cytokines and chemokines in idiopathic intracranial hypertension. Headache 2009 ; 49: 282-285.
12. Rifai N., Gillette MA and Carr SA Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006 ; 24: 971-983. (Pubitemid 44215392)
13. Marouga R., David S. and Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005 ; 382: 669-678. (Pubitemid 40890994)
14. Lehmensiek V., Sussmuth SD, Brettschneider J., et al. Proteome analysis of cerebrospinal fluid in Guillain-Barre syndrome (GBS). J Neuroimmunol 2007 ; 185: 190-194. (Pubitemid 46497448)
15. Friedman DI and Jacobson DM Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002 ; 59: 1492-1495. (Pubitemid 35387052)
16. Classification Committee of the International Headache Society. International classification of headache disorders, 2nd ed. Revision of criteria for 8.2 medication-overuse headache. Cephalalgia 2005 ; 25: 460-465.
17. Lehmensiek V., Sussmuth SD, Tauscher G., et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007 ; 13: 840-849. (Pubitemid 351540854)
18. Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin Wochenschr 1974 ; 52: 1158-1164.
19. Tumani H., Pfeifle M., Lehmensiek V., et al. Candidate biomarkers of chronic inflammatory demyelinating poly-neuropathy (CIDP): proteome analysis of cerebrospinal fluid. J Neuroimmunol 2009 ; 214: 109-112.
20. Maktabi MA, Heistad DD and Faraci FM Effects of angiotensin II on blood flow to choroid plexus. Am J Physiol 1990 ; 258: H414-H418.
21. Maktabi MA, Heistad DD and Faraci FM Effects of central and intravascular angiotensin I and II on the choroid plexus. Am J Physiol 1991 ; 261: R1126-R1132.
22. Bader M., Peters J., Baltatu O., Muller DN, Luft FC and Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 2001 ; 79: 76-102. (Pubitemid 32285333)
23. Morimoto S., Cassell MD and Sigmund CD Glia-and neuron-specific expression of the renin-angiotensin system in brain alters blood pressure, water intake, and salt preference. J Biol Chem 2002 ; 277: 33235-33241. (Pubitemid 34984843)
24. Barry DI, Jarden JO, Paulson OB, Graham DI and Strandgaard S. Cerebrovascular aspects of converting-enzyme inhibition I: Effects of intravenous captopril in spontaneously hypertensive and normotensive rats. J Hypertens 1984 ; 2: 589-597. (Pubitemid 15188009)
25. Arregui A. and Iversen LL Angiotensin-converting enzyme: presence of high activity in choroid plexus of mammalian brain. Eur J Pharmacol 1978 ; 52: 147-150. (Pubitemid 9197615)
26. Correa FM, Plunkett LM and Saavedra JM Quantitative distribution of angiotensin-converting enzyme (kininase II) in discrete areas of the rat brain by autoradiography with computerized microdensitometry. Brain Res 1986 ; 375: 259-266.
27. Maktabi MA, Stachovic GC and Faraci FM Angiotensin II decreases the rate of production of cerebrospinal fluid. Brain Res 1993 ; 606: 44-49. (Pubitemid 23084890)
28. Chodobski A., Szmydynger-Chodobska J. and Johanson CE Angiotensin II regulates choroid plexus blood flow by interacting with the sympathetic nervous system and nitric oxide. Brain Res 1999 ; 816: 518-526. (Pubitemid 29225402)
29. Greenland KJ and Sernia C. Oestrogenic regulation of brain angiotensinogen. J Neuroendocrinol 2004 ; 16: 508-515. (Pubitemid 38878282)
30. Morello N., Tonoli E., Logrand F., et al. Haemopexin affects iron distribution and ferritin expression in mouse brain. J Cell Mol Med 2009 ; 13: 4192-4204.
31. Mollan SP, Ball AK, Sinclair AJ, et al. Idiopathic intracranial hypertension associated with iron deficiency anaemia: a lesson for management. Eur Neurol 2009 ; 62: 105-108.
32. Castano EM, Roher AE, Esh CL, Kokjohn TA and Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006 ; 28: 155-163.
33. Roher AE, Maarouf CL, Sue LI, Hu Y., Wilson J. and Beach TG Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009 ; 14: 493-501.
34. Brettschneider J., Mogel H., Lehmensiek V., et al. Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem Res 2008 ; 33: 2358-2363.
35. Hansson SF, Puchades M., Blennow K., Sjogren M. and Davidsson P. Validation of a prefractionation method followed by two-dimensional electrophoresis-applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Sci 2004 ; 2: 7.
36. Steckley JL, Dyment DA, Sadovnick AD, Risch N., Hayes C. and Ebers GC Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Canadian Collaborative Study Group. Neurology 2000 ; 54: 729-732. (Pubitemid 30082946)
37. Tumani H., Lehmensiek V., Rau D., et al. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett 2009 ; 452: 214-217.
38. Tumani H., Lehmensiek V., Lehnert S., Otto M. and Brettschneider J. 2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Rev Proteomics 2010 ; 7: 29-38.
39. Brown MS and Goldstein JL The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997 ; 89: 331-340. (Pubitemid 27220877)
40. Tumani H., Teunissen C., Sussmuth S., Otto M., Ludolph AC and Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diagn 2008 ; 8: 479-494. (Pubitemid 351962092)